Trevi Therapeutics, Inc.
(NASDAQ : TRVI)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
MRKMerck & Co., Inc. 2.35%78.970.7%$1568.32m
JNJJohnson & Johnson 2.99%164.900.7%$1006.99m
PFEPfizer Inc. 1.95%42.130.9%$934.75m
ABBVAbbVie, Inc. 0.19%107.631.9%$683.19m
BMYBristol-Myers Squibb Co. 0.94%57.481.0%$657.54m
LLYEli Lilly & Co. 0.96%241.281.1%$615.22m
AZNAstraZeneca Plc 1.70%60.301.0%$372.54m
NVSNovartis AG 0.93%83.110.2%$175.98m
GSKGlaxoSmithKline Plc 1.63%39.280.2%$162.58m
RGENRepligen Corp. 1.91%268.826.8%$120.21m
NVONovo Nordisk A/S 1.33%104.800.1%$91.83m
VTRSViatris, Inc. 0.33%13.540.0%$90.90m
EDSAEdesa Biotech, Inc. 5.81%8.190.0%$74.98m
SNYSanofi 0.02%48.040.2%$62.89m
CRVSCorvus Pharmaceuticals, Inc. 2.60%4.740.7%$57.97m

Company Profile

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.